Abstract: Provided are a method for assaying a specific IgM antibody and a total antibody for the 2019 novel coronavirus (2019-nCOV), a method for determining whether subjects are infected with 2019-nCOV, and a virus antigen and a kit for carrying out the above-mentioned detection.

Abstract: Provided are a method for diagnosing nasopharyngeal carcinoma on the basis of the anti-EB virus (EBV) antibody level and a kit used for the method. Also provided are a polypeptide encoded by a BNLF2b gene in EB virus used for the above-mentioned diagnosis and the use thereof for diagnosing nasopharyngeal carcinoma.

Abstract: Provided is a cell-penetrating peptide, which can deliver a variety of biological macromolecules, such as proteins, antibodies, nucleic acids and so on into cells across a membrane. In addition, further provided are a fusion protein, conjugate and complex containing the cell-penetrating peptide, and a use of the cell-penetrating peptide.

Abstract: In the field of Hepatitis B virus (HBV) detection, disclosed are a method for detecting HBcAg by means of using a double antibody sandwich method, and an antibody and kit for detecting HBcAg; also included is a monoclonal antibody that can be used in the immunological detection of HBcAg in a tissue or cell sample.

Abstract: A multimerization delivery system that can be used to deliver a cargo molecule intracellularly. The multimerization delivery system can achieve high-efficiency endocytosis of a cargo molecule and high-efficiency release thereof from an endocytic vesicle, significantly improving the cytoplasmic delivery efficiency of the cargo molecule. Once the cargo molecule is available in the cytoplasm, the cargo molecule can play any role related thereto. The multimerization delivery system provides an effective means for affecting the biological mechanisms and pathways of cells, and can be used in various fields such as research, treatment, and diagnosis.

Abstract: A kit for quantitatively detecting HBsAg and a method for quantitatively detecting an HBsAg content in a sample containing HBsAg. The kit comprises a first antibody specifically binding to HBsAg and a reagent composition. The reagent composition comprises tris(2-carboxyethyl)phosphine hydrochloride (TCEP) and urea.

Abstract: A fusion protein and a complex containing same, capable of being used for the intracellular delivery of cargo molecules. The fusion protein and complex can implement the efficient release of cargo molecules from endocytic vesicles, thereby significantly improving the cytoplasmic delivery efficiency of the cargo molecules. One cargo molecules can be obtained in cytoplasms, they can exert any function related thereto. The fusion protein and complex provide effective means for affecting biological mechanisms and pathways of cells, and can be used in various fields such as research, treatment, and diagnosis.

Abstract: The invention relates to a truncated rotavirus VP4 protein, a sequence encoding the same, a method for preparing the same, and a pharmaceutical composition and a vaccine comprising the protein, wherein the protein, the pharmaceutical composition and the vaccine are useful for preventing, alleviating or treating rotavirus infection and a disease caused by rotavirus infection, such as rotavirus gastroenteritis and diarrhea. The invention further relates to use of the protein in the manufacture of a pharmaceutical composition or a vaccine for preventing, alleviating or treating rotavirus infection and a disease caused by rotavirus infection, such as rotavirus gastroenteritis and diarrhea.

Abstract: The present invention belongs to the field of biomedical laboratory science, and provides a specific antibody for AMH and uses thereof.

Abstract: The invention provides a kit for full-range detection of C-reactive protein based on chemiluminescence immunoassay and a method for full-range detection of C-reactive protein. The kit comprises an R1 reagent, an M reagent, an R2 reagent, a pre-excitation solution and an excitation solution. The R1 reagent, that is a sample treatment solution, is a 0.5M citric acid solution (pH 3.0-3.5, which is adjusted by disodium hydrogen phosphate dodecahydrate). The present invention also provides a kit for full-range detection of C-reactive protein, which comprises a flat-bottomed plate-type chemiluminescence plate coated with a first antibody, a sample treatment solution, a second antibody labeled with horseradish peroxidase (HRP) or alkaline phosphatase (AP), a color developing solution. The invention also provides a method for full-range detection of C-reactive protein using the kit. Both the first antibody and the second antibody are monoclonal antibodies that can specifically react with C-reactive protein.

Abstract: A kit for quantitatively detecting HBsAg and a method for quantitatively detecting an HBsAg content in a sample containing HBsAg. The kit comprises a first antibody specifically binding to HBsAg and a reagent composition. The reagent composition comprises tris(2-carboxyethyl)phosphine hydrochloride (TCEP) and urea.

Abstract: The present invention relates to a detection mechanism for polymerase chain reaction and a polymerase chain reaction device, wherein the detection mechanism comprises at least one excitation module group, each of the excitation module groups comprising two excitation modules for providing excitation light with two wavelengths; an excitation optical fiber, connected to the excitation modules, the excitation optical fiber transmitting the excitation light to at least one reaction tube, each of the reaction tubes receiving excitation light with two wavelengths; a receiving optical fiber, for collecting and transmitting a fluorescent signal from the reaction tube; at least one receiving module group, connected to the receiving optical fiber, each of the receiving module groups comprising two receiving modules, to respectively receive the fluorescent signal of two wavelengths from the same said reaction tube, and convert the fluorescent signal into an electrical signal for output; the detection mechanism is config

Abstract: The invention relates to a truncated rotavirus VP4 protein, a sequence encoding the same, a method for preparing the same, and a pharmaceutical composition and a vaccine comprising the protein, wherein the protein, the pharmaceutical composition and the vaccine are useful for preventing, alleviating or treating rotavirus infection and a disease caused by rotavirus infection, such as rotavirus gastroenteritis and diarrhea. The invention further relates to use of the protein in the manufacture of a pharmaceutical composition or a vaccine for preventing, alleviating or treating rotavirus infection and a disease caused by rotavirus infection, such as rotavirus gastroenteritis and diarrhea.

Abstract: The invention relates to a truncated rotavirus VP4 protein, a sequence encoding the same, a method for preparing the same, and a pharmaceutical composition and a vaccine comprising the protein, wherein the protein, the pharmaceutical composition and the vaccine are useful for preventing, alleviating or treating rotavirus infection and a disease caused by rotavirus infection, such as rotavirus gastroenteritis and diarrhea. The invention further relates to use of the protein in the manufacture of a pharmaceutical composition or a vaccine for preventing, alleviating or treating rotavirus infection and a disease caused by rotavirus infection, such as rotavirus gastroenteritis and diarrhea.

Abstract: Disclosed are a reaction tube for nucleic acid amplification capable of controlling a liquid circulation path, a reaction apparatus for nucleic acid amplification comprising the reaction tube, and a method for amplifying nucleic acid comprising a step of using the reaction tube. Also disclosed are a kit comprising the reaction tube, and use of the reaction tube in preparation of a kit.

Abstract: A ribonucleic acid (RNA) reverse transcription amplification method, comprising the steps of reverse transcription of RNA into cDNA and immediate amplification of cDNA, characterized in that the process of reverse transcription of RNA into cDNA is completed during the process that a cDNA amplification reaction system is heated to reach the reaction condition for cDNA amplification. The RNA reverse transcription amplification method can combine the reaction condition for reverse transcription of RNA into cDNA with the reaction condition for cDNA amplification, thereby significantly shorten the time required for RNA reverse transcription amplification. And in the whole process of RNA reverse transcription amplification, there is no need to change the instrument temperature, and thus, it is possible to achieve detection at any time.

Abstract: The invention belongs to the fields of medicine and immunology, particularly, the field of immunological diagnosis. In particular, the invention discloses a method for assessing whether a subject is at risk of developing human cytomegalovirus (HCMV) active infection and a kit therefore. The method comprises the steps of: (1) determining the level of an antibody against a HCMV protein in a body fluid sample from the subject; and (2) comparing the level with a predetermined reference value, wherein if the level is below the predetermined reference value, the subject is determined to be at risk of developing HCMV active infection. In addition, the invention also discloses a method for screening a candidate drug which is capable of improving the ability of a subject to resist human cytomegalovirus (HCMV) active infection, and a kit therefore.

Abstract: Disclosed are a reaction tube for nucleic acid amplification capable of controlling a liquid circulation path, a reaction apparatus for nucleic acid amplification comprising the reaction tube, and a method for amplifying nucleic acid comprising a step of using the reaction tube. Also disclosed are a kit comprising the reaction tube, and use of the reaction tube in preparation of a kit.

Abstract: Disclosed are a method for diagnosing whether a subject is suffering from active tuberculosis, a method for determining the therapeutic effect of a therapy on active tuberculosis, a method for screening a candidate drug capable of treating active tuberculosis, and a kit comprising a specific stimulating agent and a reagent for detecting the level of IL-6, the method and kit belong to the fields of molecular biology, immunology and disease diagnosis.

Abstract: The present invention relates to a detection mechanism for polymerase chain reaction and a polymerase chain reaction device, wherein the detection mechanism comprises at least one excitation module group, each of the excitation module groups comprising two excitation modules for providing excitation light with two wavelengths; an excitation optical fiber, connected to the excitation modules, the excitation optical fiber transmitting the excitation light to at least one reaction tube, each of the reaction tubes receiving excitation light with two wavelengths; a receiving optical fiber, for collecting and transmitting a fluorescent signal from the reaction tube; at least one receiving module group, connected to the receiving optical fiber, each of the receiving module groups comprising two receiving modules, to respectively receive the fluorescent signal of two wavelengths from the same said reaction tube, and convert the fluorescent signal into an electrical signal for output; the detection mechanism is config